Full Breakdown
Argenx to Acquire Forte Biosciences in $2.2 Billion Deal
7/28/2026, 8:49:20 AM
Core Transaction Details
Argenx announced that it will purchase Dallas-based Forte Biosciences in an all-cash transaction valued at roughly $2.2 billion. The offer prices Forte at $77 per share, representing a 41 % premium to the biotech’s closing price on the prior trading day. The acquisition is being completed through a cash payment, with no mention of additional consideration.
Strategic Context
The deal arrives amid a broader wave of consolidation in the biopharma sector, where midsize companies are actively seeking acquisition targets to broaden their therapeutic portfolios. Argenx, headquartered in Belgium, has emerged as a leading player in immunology, largely on the back of its marketed antibody Vyvgart. Vyvgart, approved for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, has seen its label expanded and sales steadily rise, positioning Argenx to leverage Forte’s pipeline for further growth in autoimmune disease treatment.
Financial and Operational Data
- Transaction value: approximately $2.2 billion in cash.
- Share price: $77 per Forte share, a 41 % premium to the previous close.
- Forte location: Dallas, Texas.
- Argenx primary operations: Belgium.
- Lead product: Vyvgart, with expanding indications and increasing revenue streams.
Official Statements & Responses
Argenx indicated that the acquisition will “expand its immunology pipeline,” signaling an intent to deepen its presence in the autoimmune-disease space. The company framed the purchase as a continuation of the sector’s ongoing acquisition run, suggesting confidence that Forte’s assets will complement existing programs and accelerate development timelines.
Implications for the Immunology Market
By integrating Forte’s research capabilities, Argenx aims to broaden its portfolio of therapies targeting autoimmune conditions, potentially accelerating the delivery of new treatments to patients. The transaction also underscores the competitive pressure on midsize biotechs to align with larger, financially robust partners, a trend that may reshape pipeline strategies and partnership dynamics across the immunology landscape.
